Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Use Of Specialty Drug Tiers Jumps Among Employer Plans In 2013, Survey Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The increase in the number of employer plans with four or more formulary tiers in 2013 is notable because the percentage remained in the 13% to 14% range for the past three years, according to figures from an annual survey by the Kaiser Family Foundation and the Health Research and Educational Trust.

You may also be interested in...



Drug Pricing Among Range Of Issues Senators Want HHS Nominee Becerra To Work On

Senate Finance confirmation hearing concluded without a vote on Xavier Becerra’s nomination as Health and Human Services Department secretary. Republicans continued to express concerns with his background and views. But he is expected to win enough votes to clear the committee.

HHS Secretary Nominee Becerra Plans ‘Swift’ Action On Drug Pricing Reform

‘We need the pharmaceutical industry … to always feel we’ve got their back to innovate,’ Becerra tells Senate Committee. ‘But we have to ensure that we’re getting our dollars’ worth.’

As CMS Chief, Brooks-LaSure Could Turn Quickly To Medicare Drug Spending Reforms

Chiquita Brooks-LaSure would be in a key position to implement the Biden Administration’s drug pricing priorities and is familiar with the balancing act needed when considering competing interests among stakeholders as policies are shaped.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel